239 related articles for article (PubMed ID: 30959948)
1. Association between Polymorphisms of
Chang HH; Hsueh YS; Cheng YW; Ou HT; Wu MH
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30959948
[TBL] [Abstract][Full Text] [Related]
2. Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome.
Gambineri A; Tomassoni F; Gasparini DI; Di Rocco A; Mantovani V; Pagotto U; Altieri P; Sanna S; Fulghesu AM; Pasquali R
J Clin Endocrinol Metab; 2010 Oct; 95(10):E204-8. PubMed ID: 20660041
[TBL] [Abstract][Full Text] [Related]
3. Metformin resistance alleles in polycystic ovary syndrome: pattern and association with glucose metabolism.
Schweighofer N; Lerchbaum E; Trummer O; Schwetz V; Pieber T; Obermayer-Pietsch B
Pharmacogenomics; 2014 Feb; 15(3):305-17. PubMed ID: 24533710
[TBL] [Abstract][Full Text] [Related]
4. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.
Tarasova L; Kalnina I; Geldnere K; Bumbure A; Ritenberga R; Nikitina-Zake L; Fridmanis D; Vaivade I; Pirags V; Klovins J
Pharmacogenet Genomics; 2012 Sep; 22(9):659-66. PubMed ID: 22735389
[TBL] [Abstract][Full Text] [Related]
5. The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial.
Pedersen AJT; Stage TB; Glintborg D; Andersen M; Christensen MMH
Basic Clin Pharmacol Toxicol; 2018 Feb; 122(2):239-244. PubMed ID: 28834135
[TBL] [Abstract][Full Text] [Related]
6. Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai.
Zhou Y; Ye W; Wang Y; Jiang Z; Meng X; Xiao Q; Zhao Q; Yan J
Int J Clin Exp Pathol; 2015; 8(8):9533-42. PubMed ID: 26464716
[TBL] [Abstract][Full Text] [Related]
7. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin.
Shikata E; Yamamoto R; Takane H; Shigemasa C; Ikeda T; Otsubo K; Ieiri I
J Hum Genet; 2007; 52(2):117-122. PubMed ID: 17111267
[TBL] [Abstract][Full Text] [Related]
8. Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine.
Meyer MJ; Seitz T; Brockmöller J; Tzvetkov MV
PLoS One; 2017; 12(12):e0189521. PubMed ID: 29236753
[TBL] [Abstract][Full Text] [Related]
9. Effects of single-nucleotide polymorphism on the pharmacokinetics and pharmacodynamics of metformin.
Li S; Xu B; Fan S; Kang B; Deng L; Chen D; Yang B; Tang F; He Z; Xue Y; Zhou JC
Expert Rev Clin Pharmacol; 2022 Sep; 15(9):1107-1117. PubMed ID: 36065506
[TBL] [Abstract][Full Text] [Related]
10. Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review.
Mofo Mato EP; Guewo-Fokeng M; Essop MF; Owira PMO
Medicine (Baltimore); 2018 Jul; 97(27):e11349. PubMed ID: 29979413
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms of organic cation transporters 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes mellitus: a systematic review protocol.
Mato EPM; Guewo-Fokeng M; Faadiel Essop M; Owira PMO
Syst Rev; 2018 Jul; 7(1):105. PubMed ID: 30041690
[TBL] [Abstract][Full Text] [Related]
12. Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake.
Choi MK; Song IS
Biopharm Drug Dispos; 2012 Apr; 33(3):170-8. PubMed ID: 22415520
[TBL] [Abstract][Full Text] [Related]
13. Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09).
Joerger M; van Schaik RH; Becker ML; Hayoz S; Pollak M; Cathomas R; Winterhalder R; Gillessen S; Rothermundt C
Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):167-72. PubMed ID: 25753371
[TBL] [Abstract][Full Text] [Related]
14. Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with Type 2 diabetes.
Dujic T; Causevic A; Bego T; Malenica M; Velija-Asimi Z; Pearson ER; Semiz S
Diabet Med; 2016 Apr; 33(4):511-4. PubMed ID: 26605869
[TBL] [Abstract][Full Text] [Related]
15. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome.
Li M; Yang M; Zhou X; Fang X; Hu W; Zhu W; Wang C; Liu D; Li S; Liu H; Yang G; Li L
J Clin Endocrinol Metab; 2015 Apr; 100(4):1485-93. PubMed ID: 25675380
[TBL] [Abstract][Full Text] [Related]
16. Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome.
Sam S; Ehrmann DA
Diabetologia; 2017 Sep; 60(9):1656-1661. PubMed ID: 28770330
[TBL] [Abstract][Full Text] [Related]
17. [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
Hahn S; Quadbeck B; Elsenbruch S; Gärtner R; Finke R; Mann K; Janssen OE
Dtsch Med Wochenschr; 2004 May; 129(19):1059-64. PubMed ID: 15136950
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function.
Chen L; Takizawa M; Chen E; Schlessinger A; Segenthelar J; Choi JH; Sali A; Kubo M; Nakamura S; Iwamoto Y; Iwasaki N; Giacomini KM
J Pharmacol Exp Ther; 2010 Oct; 335(1):42-50. PubMed ID: 20639304
[TBL] [Abstract][Full Text] [Related]
19. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1.
Kimura N; Masuda S; Tanihara Y; Ueo H; Okuda M; Katsura T; Inui K
Drug Metab Pharmacokinet; 2005 Oct; 20(5):379-86. PubMed ID: 16272756
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer.
Berstein LM; Iyevleva AG; Vasilyev D; Poroshina TE; Imyanitov EN
Cell Cycle; 2013 Dec; 12(23):3681-8. PubMed ID: 24145224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
